Free tool
FAERS Monitor: Onivyde
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207793 or its brand name (Onivyde, Irinotecan Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
9,837
Serious
9,369
95% of reports
Hospitalization
3,831
Death reported
1,809
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea1,225
- off label use980
- myelosuppression719
- nausea645
- vomiting569
- malignant neoplasm progression548
- febrile neutropenia538
- death512
- neutropenia468
- neuropathy peripheral443
- disease progression426
- fatigue420
- pyrexia383
- neutrophil count decreased354
- asthenia343
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 9 |
| 2006 | 6 |
| 2007 | 2 |
| 2008 | 143 |
| 2009 | 84 |
| 2010 | 123 |
| 2011 | 224 |
| 2012 | 291 |
| 2013 | 243 |
| 2014 | 158 |
| 2015 | 335 |
| 2016 | 312 |
| 2017 | 313 |
| 2018 | 414 |
| 2019 | 488 |
| 2020 | 548 |
| 2021 | 638 |
| 2022 | 863 |
| 2023 | 1,022 |
| 2024 | 1,083 |
| 2025 | 1,475 |
| 2026 | 1,052 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,322 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 719 | 43.5 | 40.5 | 29,290 |
| neutrophil count decreasedSignal | 354 | 18.7 | 16.9 | 5,882 |
| febrile neutropeniaSignal | 538 | 17.5 | 16.1 | 8,298 |
| malignant neoplasm progressionSignal | 548 | 11.5 | 10.6 | 5,239 |
| neuropathy peripheralSignal | 443 | 10.0 | 9.1 | 3,579 |
| disease progressionSignal | 426 | 7.7 | 7.0 | 2,491 |
| neutropeniaSignal | 468 | 7.4 | 6.8 | 2,583 |
| diarrhoeaSignal | 1,225 | 4.1 | 3.9 | 2,910 |
| vomitingSignal | 569 | 2.6 | 2.4 | 566 |
| off label useSignal | 980 | 2.4 | 2.3 | 828 |
| pyrexiaSignal | 383 | 2.4 | 2.1 | 306 |
| asthenia | 343 | 2.0 | 1.8 | 161 |
| nausea | 645 | 1.7 | 1.6 | 211 |
| death | 512 | 1.3 | 1.2 | 31 |
| fatigue | 420 | 1.2 | 1.1 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.